Dr. Alex F. Herrera
Claim this profileCity of Hope Medical Center
Expert in Lymphoma
Studies Hodgkin's Lymphoma
17 reported clinical trials
38 drugs studied
About Alex F. Herrera
Education:
- Graduated Summa Cum Laude with an undergraduate degree from Princeton University, focusing on pre-med studies.
- Earned a Medical Degree from Harvard Medical School.
Experience:
- Completed an Internal Medicine Residency at Brigham and Women's Hospital.
- Undertook a Hematology/Oncology Fellowship at Dana-Farber Cancer Institute.
- Specializes in immunotherapy and hematopoietic stem cell transplantation with a focus on lymphoma, particularly Hodgkin lymphoma, at City of Hope Medical Center.
- Published significant research, including a lead-authored paper in The New England Journal of Medicine.
Area of expertise
1Lymphoma
Global LeaderCD19 positive
Stage IV
Stage I
2Hodgkin's Lymphoma
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Alex F. Herrera is currently running
Immunotherapy
for Hodgkin's Lymphoma
This trial is testing a new treatment called mosunetuzumab against the usual treatment, rituximab, for patients with a type of cancer called NLPHL. Both treatments help the immune system find and kill cancer cells by targeting a specific protein on these cells. The goal is to see if mosunetuzumab can improve survival better than rituximab.
Recruiting1 award Phase 2
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity on transplantation.
Recruiting1 award Phase 224 criteria
More about Alex F. Herrera
Clinical Trial Related5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Alex F. Herrera has experience with
- Nivolumab
- Brentuximab Vedotin
- Etoposide
- Cyclophosphamide
- Rituximab
- Doxorubicin Hydrochloride
Breakdown of trials Alex F. Herrera has run
Lymphoma
Hodgkin's Lymphoma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alex F. Herrera specialize in?
Alex F. Herrera focuses on Lymphoma and Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved CD19 positive patients, or patients who are Stage IV.
Is Alex F. Herrera currently recruiting for clinical trials?
Yes, Alex F. Herrera is currently recruiting for 7 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Alex F. Herrera has studied deeply?
Yes, Alex F. Herrera has studied treatments such as Nivolumab, Brentuximab Vedotin, Etoposide.
What is the best way to schedule an appointment with Alex F. Herrera?
Apply for one of the trials that Alex F. Herrera is conducting.
What is the office address of Alex F. Herrera?
The office of Alex F. Herrera is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.